Sex and gender differences in COVID-19: an Italian local register-based study

Francesca Fortunato,1 Domenico Martinelli,1 Sergio Lo Caputo,2 Teresa Santantonio,2 Vitangelo Dattoli,3 Pier Luigi Lopalco,4 Rosa Prato4

ABSTRACT
Objectives The present study aimed to explore differences in COVID-19 outcomes between male and female cases in the Apulian District of Foggia, Italy.

Design and setting We performed a retrospective epidemiological study among all COVID-19 confirmed cases that occurred in the Apulian District of Foggia from 29 February to 30 June 2020. The surveillance data from a regional registry (GINA-COVID) were used.

Main outcomes The main outcome measures were the proportion of hospitalisations, virus clearance and the case fatality rate.

Results A total of 1175 cases (50.7% female; median age: 55 years) were identified among 55131 tests performed. The proportion of hospitalisation with COVID-19 diagnosis was 45.4% in men versus 37.9% in women (p<0.01), while the average length of stay in hospitals was 31.3±14.6 days in women versus 26.8±14.4 days in men (p<0.01). The proportion of cases who achieved virus clearance was higher in women (84.2%; days to clearance: 28.0±12.1) than in men (79.3%; days to clearance: 29.4±12.9; p<0.05). Men were associated with a significantly higher risk of dying from COVID-19 than women (case fatality rate 16.1% vs 10.4%; p<0.01). The proportion of cases who achieved virus clearance was higher in women (84.2%; days to clearance: 28.0±12.1) than in men (79.3%; days to clearance: 29.4±12.9; p<0.05). Men were associated with a significantly higher risk of dying from COVID-19 than women (case fatality rate 16.1% vs 10.4%; p<0.01). The mean time, from diagnosis to death, was 14.5±14.4 days in women compared with 10.6±10.7 days in men (p<0.01). The male sex, age ≥55 years and presence of at least one underlying comorbidity significantly raised the risk of hospitalisation, persistent infection and death (p<0.05).

Conclusions This study suggests that more attention should be paid to sex as a variable for the interpretation of COVID-19 data. Sex-disaggregated data will help clinicians to make appropriate patient-tailored medical decisions.

INTRODUCTION
SARS-CoV-2 is a novel coronavirus causing the current pandemic, which has resulted in millions of infections and hundreds of thousands of deaths worldwide. As of 10 March 2021, a total of 3 069 625 cases of confirmed SARS-CoV-2 have been reported in Italy with a case fatality rate (CFR) of 3.2%.1,2, The clinical manifestations of SARS-CoV-2 vary from asymptomatic infection to severe or critical disease.

Older age and comorbidities such as hypertension, cardiovascular disease, diabetes and chronic respiratory disease are associated with severe disease and death.3,5 Sex and gender have been identified as additional risk factors contributing to heterogeneous COVID-19 outcomes.2 Indeed, several studies have reported sex bias in COVID-19 case fatalities. It is observed that men have a higher risk of developing a severe form of the disease compared with women, highlighting the importance of sex-disaggregated data of COVID-19 cases.6 The initial reports from China followed by data from several European countries have shown similar numbers of confirmed cases between men and women.7,8 However, the severity of COVID-19, measured as hospitalisation, admission to intensive care units (ICUs) and fatality rate, is twofold higher in men than women.8 Studies in China, South Korea, USA, UK and Italy

To cite: Fortunato F, Martinelli D, Lo Caputo S, et al. Sex and gender differences in COVID-19: an Italian local register-based study. BMJ Open 2021;11:e051506. doi:10.1136/bmjopen-2021-051506

Prepublication history for this paper is available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2021-051506).

Received 22 March 2021
Accepted 13 September 2021

Strengths and limitations of this study
- This study provides sex-disaggregated data of COVID-19 cases at a district level, in Italy, contributing to a better understanding of who is being impacted the most by the pandemic and promoting a patient-tailored treatment approach.
- The robust methodology of the present study enabled to accurately correlate the case demographics with COVID-19 clinical response.
- The data related to the viral clearance, which reflect the diversified course of the disease according to the individual immune response, are confirmatory of sex difference in COVID-19.
- The data collected are highly homogeneous as they are strictly related to the first epidemic wave and provide an accurate picture of the impact of sex and age on COVID-19 outcomes in Italy during the initial phase of the pandemic.
- As the majority of the sex-disaggregated data available in the literature, the data presented in our study are not adjusted for lifestyle, profession, social or behavioural differences.
have reported higher CFRs and worst disease outcomes in male cases than in female cases.\textsuperscript{7,10-14} In some of these studies, the higher fatality rate in men was observed even after adjusting for confounding factors such as age and comorbidities.\textsuperscript{7,14} Additionally, in Italy, the higher fatality rate in men (age range: 40–80 years) is confirmed when the healthcare worker population is selectively studied.\textsuperscript{1}

The reasons for the differences in COVID-19 outcome and progression between men and women remain unclear. On one hand, biological factors, such as chromosomal and hormonal differences between men and women, may influence their susceptibility to infections, immune responses and progression of the disease.\textsuperscript{6,9,15,16} On the other hand, gender-related factors including psychological, social and behavioural differences between men and women may affect SARS-CoV-2 exposure, presence of comorbidities, treatment initiation and compliance, and COVID-19 mortality.\textsuperscript{17,18}

In this study, we used the surveillance data from a regional registry containing all confirmed cases of COVID-19 that occurred in the Foggia District (Apulia region, Italy), as of late June 2020, after the end of the first epidemic wave. We aimed to explore the sex differences in hospitalisation, virus clearance and deaths.

**METHODS**

**Study population and design**

We conducted a retrospective epidemiological study among COVID-19 cases that occurred in the Foggia District, Apulia region, Italy, from 29 February to 30 June 2020. Foggia District is the third largest Apulian District, with an estimated population of 616,310 residents (51% women) as of 1 January 2020.\textsuperscript{19}

We used the surveillance data from a regional registry (GIAVA-COVID), which was developed based on the WHO Go.Data outbreak investigation tool to manage the emergency.\textsuperscript{20} GIAVA-COVID includes functionalities for investigation and follow-up of cases and contacts, contact tracing, laboratory and clinical data collection. The collected information includes age, sex, residence location, date of disease onset, date of diagnosis, date of hospital admission, date of COVID-19 test results (positive or negative), date of death, presence of underlying diseases, case outcomes (hospitalisation, virus clearance and death) and disease severity (mild, moderate, severe or critical).\textsuperscript{21} The disease classification was duly updated according to clinical evolution of each case.

This study included all laboratory-confirmed cases defined as any person meeting the laboratory criterion (ie, detection of SARS-CoV-2 nucleic acid or antigen in a clinical specimen).\textsuperscript{22}

The proportion of hospitalisation was defined as the proportion of infected individuals undergoing hospitalisation among the total number of infected individuals. The proportion of individuals who achieved virus clearance was defined as the proportion of clinically recovered individuals with laboratory evidence of viral RNA clearance from the upper respiratory tract (two serial negative PCR tests at least 24 hours apart) among the total number of infected individuals. The CFR was defined as the proportion of deaths among the total number of confirmed cases.

**Statistical analysis**

Categorical variables were summarised as counts and percentages in each category. Data for continuous variables were expressed as medians (IQRs and means (±SD)). Normality of data was tested by the Kolmogorov-Smirnov test. Differences in continuous variables were assessed with Student’s t-test or Mann-Whitney U test, depending on whether continuous variables were normally distributed or not, respectively. Significant differences in categorical variables were assessed using the χ² test or Fisher’s exact test when appropriate and the OR with 95% CI. Multivariate logistic regression analysis was performed to evaluate whether demographics (sex: male vs female; age group: above vs below the median age) and clinical characteristics (presence vs absence of at least one underlying medical condition) were independently associated with hospitalisation, virus clearance and deaths. The analysis was conducted with STATA/SE V.15.0.

**RESULTS**

Between 29 February and 30 June 2020, a total of 1175 cases (50.7% female; median age: 55 years, IQR: 40–71 years) were diagnosed with COVID-19 in the Foggia District, Apulia region, Italy. The female positivity rate was 2.02% among 29,475 tests performed, and the male positivity rate was 2.25% among 25,656 tests performed (χ² p<0.05).

Comparison of demographics and clinical characteristics of men versus women are shown in table 1. A total of 373 cases (31.7%) had underlying medical conditions, including cardiovascular disease (63.3%), diabetes (19.6%), chronic pulmonary disease (13.9%), cancer (10.7%), neurological diseases (9.5%), chronic kidney disease (9.4%) and obesity (with body mass index between 30 and 40kg/m² or higher) (6.7%). Nearly 50% of cases were asymptomatic or with mild disease, 14.4% had moderate disease, 20.9% developed a severe disease and 3.2% progressed to a critical stage. There was no significant difference in age, underlying comorbidities (with the exception of diabetes) and disease severity distributions between the male and female groups (table 1).

The proportion of hospitalisation among COVID-19 cases was estimated to be 41.6%, with a significant difference observed between men (45.4%) and women (37.9%; p<0.01). While the average length of stay in hospitals was significantly higher in women (31.3±14.6 days) than in men (26.8±14.4 days; p<0.01), there were more women aged ≥5 years hospitalised (p<0.01). The proportion of cases who achieved virus clearance was 82%, higher in women (84.2%; days to clearance: 28±12.1) than in men (79.3%; days to clearance: 29±12.9; p<0.05). A
total of 155 deaths occurred among all cases for an overall CFR of 13.2%. Men were associated with a significantly higher risk of dying from COVID-19 than women (16.1% vs 10.4%; \(p<0.01\)). The mean time, from diagnosis to death was higher in women (14.5±14.4 days) compared with men (10.6±10.7 days; \(p<0.01\)) (table 2).

The male sex, age \(\geq 55\) years and underlying comorbidities (presence of at least a condition among those listed in table 1) significantly raised the risk of hospitalisation, persistent infection and death (\(p<0.05\); table 3).

DISCUSSION

Our registry-based surveillance study of 1175 COVID-19 cases, well characterised from both demographic and clinical points of view, highlighted a male bias in COVID-19 outcomes. Based on the herein presented data, men are more likely to be hospitalised than women, and the proportion of male cases achieving virus clearance is lower compared with female cases. Furthermore, men require longer periods to achieve virus clearance, have a higher fatality rate and faster progression to death.

A male bias (male-to-female ratio >1.1) in COVID-19 mortality is currently reported in 75 of the 94 countries that have provided sex-disaggregated data (as of 10 March 2021). At the global level, a higher number of men are hospitalised or admitted to ICU compared with women.\(^23\) Additionally, several studies have demonstrated that men with COVID-19 are at higher risk of death and severe form of infection than women.\(^{24}^{25}\) A recent meta-analysis of 3111714 reported global cases demonstrated that,
While there is no difference in the proportion of male and female COVID-19 cases, men have higher odds of death (OR=1.39; 95% CI 1.31 to 1.47) compared with women. Similarly, our study presents a comparable proportion of other European countries. Although in the early overall sex distribution of cases observed in Italy and the Foggia District, Apulia region is in line with the male sex.

The sex distribution of confirmed cases observed in the Foggia District, Apulia region is in line with the overall sex distribution of cases observed in Italy and other European countries. Although in the early phase of the pandemic in Italy, a higher prevalence of COVID-19 was observed in men compared with women; this disproportion became less evident with the progression of the pandemic. This variability may be explained by the different surveillance approaches adopted during the pandemic since a symptom-based screening led to an underestimation of asymptomatic to mild cases during the first epidemic wave. In Italy, after the end of the first epidemic wave (30 June 2020), a higher number of male cases was observed in the 0–9, 10–19, 60–69 and 70–79 years age groups (52.7%, 50.1%, 59.5% and 57.1%, respectively) compared with female cases, whereas a nearly four times higher number of female cases was observed in the >90 years age group. On the contrary, as of 10 March 2021, the number of confirmed COVID-19 cases is slightly higher in women both in the overall Italian territory (51.4% in women vs 48.6% in men) and in Apulia (51.6% in women vs 48.4% in men).

Differences in disease incidence, morbidity and mortality between sexes have also been observed in other infectious diseases such as the severe acute respiratory syndrome coronavirus and the Middle East respiratory syndrome coronavirus with men being more susceptible than women to the infection and having a worse outcome. The difference in mortality between men and women suggests that women are either less prone to develop severe complications or are less likely to die because of severe complications.

The reasons behind these sex-related differences are probably pathogen-specific and of multifactorial origin. The three main determinants so far proposed to explain male–female disparities in SARS-CoV-2 infection are differences in immune function associated with the X chromosome, the effects of sex hormones, gender-related behavioural and sociocultural differences. For example, the localisation of ACE2 and Toll-like receptor 7 genes in the X chromosome and the monoallelic versus biallelic presence may help explain the increased risk of COVID-19 for males compared with females.

From a biological point of view, women seem to have a stronger immune system, weaker cytokine-based proinflammatory response and lower levels of ACE2, an essential component for the entrance of COVID-19 into the cells. In this context, oestrogens seem to play a key protective role. Oestrogen levels vary with age, rising in

### Table 2

| Characteristics              | Male     | Female   | OR (95% CI) | P value | Mean age (±SD), years | OR (95% CI) | P value | Median length of stay in hospital (±SD), days | OR (95% CI) | P value | Mean time-to-virus clearance (±SD), days | OR (95% CI) | P value | Deaths, no. (%) | OR (95% CI) | P value |
|------------------------------|----------|----------|-------------|---------|-----------------------|-------------|---------|-----------------------------------------------|-------------|---------|------------------------------------------|-------------|---------|---------------------------------------|-------------|---------|
| Hospitalisation, no. (%)     | 263 (45.4) | 226 (37.9) | 1.36 (1.07 to 1.73) | 0.0091 | 66.2±16.0 | 70.2±18.8 | 0.0053 | 26.8±14.4                                  | 31.3±14.6 | 0.0032 | 24 (17–35)                              | 29 (19–41) |         | 459 (79.3)                              | 502 (84.2) | 0.0278 |
| Mean age (±SD), years        |          |          |             |         |                       |             |         |                                              |             |         |                                         |             |         |                                       |             |         |
| Mean length of stay in hospital (±SD), days |          |          |             |         |                       |             |         |                                              |             |         |                                         |             |         |                                       |             |         |
| Virus clearance (yes), no. (%) |          |          |             |         |                       |             |         |                                              |             |         |                                         |             |         |                                       |             |         |
| Mean time-to-virus clearance (±SD), days |          |          |             |         |                       |             |         |                                              |             |         |                                         |             |         |                                       |             |         |
| Mean time to death (±SD), days |          |          |             |         |                       |             |         |                                              |             |         |                                         |             |         |                                       |             |         |
| Median length of stay in hospital (±SD), days |          |          |             |         |                       |             |         |                                              |             |         |                                         |             |         |                                       |             |         |
| Median length of stay in hospital (IQR), days |          |          |             |         |                       |             |         |                                              |             |         |                                         |             |         |                                       |             |         |
| Median time to death (IQR), days |          |          |             |         |                       |             |         |                                              |             |         |                                         |             |         |                                       |             |         |

### Table 3

| Characteristics                               | Hospitalisation | Virus clearance (no) | Deaths |
|-----------------------------------------------|-----------------|----------------------|--------|
| OR (95% CI) P value                           | OR (95% CI) P value | OR (95% CI) P value |        |
| Sex (male vs female)                          | 1.52 (1.15 to 2.20) P 0.003 | 1.51 (1.08 to 2.09) P 0.014 | 2.33 (1.52 to 3.58) P 0.000 |
| Age group (≥55 years vs <55 years)            | 1.83 (1.68 to 1.99) P 0.000 | 1.62 (1.47 to 1.78) P 0.000 | 2.62 (2.22 to 3.07) P 0.000 |
| At least one comorbidity (yes vs no)          | 1.99 (1.47 to 2.69) P 0.000 | 1.63 (1.16 to 2.29) P 0.004 | 1.94 (1.28 to 2.93) P 0.002 |
prepubertal individuals and decreasing with age. Thus, the age-associated decline in oestradiol levels might be an explanation for the higher susceptibility and severe progression of COVID-19 in older subjects.37

Our study highlights that, alongside sex, age and comorbidity are risk factors increasing hospitalisation and death and decreasing virus clearance. That COVID-19 severity increases with age became evident since the beginning of the pandemic. Early studies from China and Italy showed that older age was associated with a greater risk of developing acute respiratory distress syndrome, severe lung disease and death.2 5 9 A recent meta-analysis of 55 studies and 10 014 COVID-19 cases confirmed that older age (≥50 years), together with comorbidities, significantly affects the prognosis and severity of COVID-19.3 A further study investigated whether male bias in COVID-19 mortality was maintained at every age. It analysed data collated by the National Institute for Demographic Studies from national statistical agencies across England and Wales, France, Germany, Italy, the Netherlands, Portugal, Korea and Spain, including a population of 194 349 591 men and 201 715 364 women from the beginning of the pandemic until 21 June 2020. The overall male-to-female mortality sex ratio per 100 000 population was 1.4 (crude ratio 1.3). This ratio varied with age: 0.81 for subjects aged 0–9 years; 1.9 in the 40–49-year age group; 2.3 in the 50–59-year age group; 2.6 in the 60–69-year age group; and 1.65 in subjects older than 80 years.38 How the male versus female difference in mortality, hospitalisation and virus clearance progresses with age is an aspect that warrants further investigation. In this context, stratification of the sex-disaggregated data provided in our study by age group could be relevant to better understand to what extent women are genetically protected from COVID-19. Interestingly, in our study, the stratification of the population by a cut-off age of 55 years highlighted a higher hospitalisation rate in the subgroup of women aged ≥55 years, suggesting the role of the reduction of hormonal protection with age.

One of the main hypotheses that have been postulated to justify the observed sex heterogeneity in the immune response to SARS-CoV-2 infection is the different genetic profile. Increasing evidence from patient populations highlights a substantial contribution of human genetic factors to the diversified susceptibility to SARS-CoV-2 infection and/or COVID-19 severity. In this context, a differential response to COVID-19 has also been observed among individuals with ethnicity-based differences in their genetic profile.35 For instance, the distribution of the gene cluster on chromosome 3, that has been recently identified as the major genetic risk factor for severe COVID-19, differs among populations of different ethnic background (ie, Asian, European and African populations).36

Lastly, gender-related differences in lifestyles and social roles require careful considerations as they are believed to greatly influence the onset, course and outcome of COVID-19. It has been proposed that smoking and alcohol consumption, alongside poor eating habits, more frequently found in men than women, may lead to a higher incidence of comorbidities in men compared with women explaining the higher male mortality observed on a global level.17 40 However, it must be noted that no significant difference in underlying comorbidities (except for diabetes) between men and women was found in our study. There may be other behavioural and social differences favouring women as men are more reluctant to follow hand hygiene and seek preventive care.41 However, women might be more easily exposed to SARS-CoV-2 infection in both professional and household settings. Indeed, women represent 70% of the health and social care workforce and more often care for household members with COVID-19.17 40

The present study aimed to explore the differences in hospitalisation and death between men and women at the local level taking into consideration COVID-19 confirmed cases in the Apulian District of Foggia. The results are in line with what observed on a national and global level. Hospitalisation and death are hard outcomes for monitoring the course and severity of the disease. Furthermore, sex difference in virus clearance represents an added-value outcome of our study as it expresses the immune response of the host.

However, it should not be neglected that one of the main limitations of our study is that the presented data are not adjusted for lifestyle, profession, social or behavioural differences, all relevant factors that could change the interpretation of the data and could further emphasise the male bias in COVID-19 severity and fatality. This limitation is a common feature of the majority of sex-disaggregated data currently available. Indeed, due to practicability and ethical reasons, no prospective study comparing an equal number of men and women under equal conditions of viral exposure has been conducted to date. Therefore, we highlight the need of taking into account the social, familiar and professional roles, alongside biological variables, in order to fully understand the differences in COVID-19 outcome between men and women.

The main strength of our study consists in its robust methodology, which enabled an accurate evaluation of the correlation between the case demographics (especially gender) and COVID-19 clinical response. Specifically, the collection of viral clearance data highlights a statistically significant male-to-female difference and provides a plausible explanation for the observed diversified course of the disease. Furthermore, the data collected in our study are highly homogeneous as they are strictly related to the first epidemic wave and provide an accurate picture of the impact of sex and age on SARS-CoV-2 infection response in Italy during the initial phase of the pandemic. The ethnic composition of the population included in our study is also highly homogeneous and likely well representative of the Italian population or other Mediterranean European populations.

Fortunato F, et al. BMJ Open 2021;11:e051506. doi:10.1136/bmjopen-2021-051506
CONCLUSIONS
Despite a comparable incidence of COVID-19 among the two sexes, a male bias in COVID-19 mortality is observed in the majority of the countries with available sex-disaggregated data. Our study provides sex-disaggregated data for the COVID-19 cases of the Apulian district of Foggia, Italy. It demonstrates that male sex, alongside older age (age ≥55 years) and presence of at least one comorbidity, is associated with a greater risk of hospitalisation and death, and lower virus clearance. Therefore, more attention should be paid to sex as a variable for the interpretation of COVID-19 data. This study will help clinicians to make appropriate patient-tailored medical decisions based on patient sex, age and comorbidities. Future investigations providing data adjusted for gender-related factors (social, familiar and professional roles) are warranted.

Acknowledgements The authors would like to thank all the frontline health workers at hospitals and local health unit for their dedication and valuable work into pandemic control. A special thanks to Lucia Massi, Maria Rosa Valetto and Pietro Dri (Zadig, Scientific Publisher, Milan, Italy) for editorial assistance, manuscript development and writing support.

Contributors FF and RP conceptualised and designed the work, analysed and interpreted data and wrote the manuscript. DM and PLL supervised the study, coordinated regional data collection and provided statistical support. SLC, TS and VD interpreted the results and critically reviewed the advanced version of the manuscript. All authors approved the final draft of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval The study was conducted in accordance with the principles expressed in the Declaration of Helsinki 1975, as revised in 2008. As this study constituted public health surveillance, ethical approval from institutional review board was not required. All data were provided and analysed anonymously.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No additional data available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercia,l and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Francesca Fortunato http://orcid.org/0000-0003-0665-5385
Rosa Prato http://orcid.org/0000-0001-8138-5835

REFERENCES
1 COVID-19 integrated surveillance data in Italy. Available: https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-dashboard [Accessed 10 Mar 2021].
2 Falahi S, Kenarkoohi A. Sex and gender differences in the outcome of patients with COVID-19. J Med Virol 2021;93:151–2.
3 Barak MA, Aziz MA, Islam MS. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: a meta-analysis with 55 studies and 10014 cases. Heliyon 2020;6:e06584.
4 Onder G, Rezza G, Brusaforo S. Case-Fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020;323:1775–6.
5 Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934.
6 Maleki Dana P, Sadoughi F, Hallajzadeh J, et al. An insight into the sex differences in COVID-19 patients: what are the possible causes? Prehosp Disaster Med 2020;35:438–41.
7 Chen J, Bai H, Liu J, et al. Distinct clinical characteristics and risk factors for mortality in female inpatients with coronavirus disease 2019 (COVID-19): A Sex-stratified, large-scale cohort study in Wuhan, China. Clin Infect Dis 2020;71:3188–95.
8 Methard C, Regitz-Zagrosek V, Neuhauser HK, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ 2020;11:29.
9 Klein SL, Dhakal S, Ursin RL, et al. Biological sex impacts COVID-19 outcomes. PLoS Pathog 2020;16:e1008570.
10 Borghesi A, Ziglani A, Mascia D, et al. Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients. Radiol Med 2020;125:461–4.
11 Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;369:m1091.
12 Dudley JP, Lee NT. Disparities in age-specific morbidity and mortality from SARS-CoV-2 in China and the Republic of Korea. Clin Infect Dis 2020;71:863–5.
13 Gavin W, Campbell E, Zaidi S-A, et al. Clinical characteristics, outcomes and prognosticators in adult patients hospitalized with COVID-19. Am J Infect Control 2021;49:158–65.
14 Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19–related death using OpenSAFE. Nature 2020;584:430–4.
15 Bienvenu LA, Noonan J, Wang X, et al. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. Cardiovasc Res 2020;116:2197–206.
16 Scully EP, Haverfield J, Ursin RL, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol 2020;20:42–7.
17 Cataldo C, Masella R, Claudia C, Roberta M. Gender-Related sociocultural differences and COVID-19: what influence on the effects of the pandemic? Epidemiol Prev 2020;44:398–9.
18 Griffith DM, Sharma G, Holliday CS, et al. Men and COVID-19: a biopsychosocial approach to understanding sex differences in mortality and recommendations for practice and policy interventions. Prev Chronic Dis 2020;17:E63.
19 Statistica demografiche ISTAT. Available: http://demo.istat.it/pop2020/index.html [Accessed 1 Feb 2021].
20 Go Data: managing complex data in outbreaks. Available: https://www.who.int/godata [Accessed 1 Feb 2021].
21 Clinical management of COVID-19. Available: https://www.who.int/publications/item/clinical-management-of-covid-19 [Accessed 10 Mar 2021].
22 Case definition for coronavirus disease 2019 (COVID-19), as of 3 December 2020. Available: https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition [Accessed 1 Feb 2021].
23 Global health 50/50. Available: https://globalhealth5050.org/the-sex-gender-and-health-50-50-project [Accessed 10 Mar 2021].
24 Kragholm K, Andersen MP, Gerds TA, et al. Association between male sex and outcomes of Coronavirus Disease 2019 (COVID-19) - a Danish nationwide, register-based study. Clin Infect Dis 2020;ciaa924.
25 Lakbar I, Luque-Paz D, Mege J-L, et al. COVID-19 gender susceptibility and outcomes: a systematic review. PLoS One 2020;15:e0241827.
26 Peckham H, de Gruiter NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 2020;11:1–10.
27 European Centre for Disease Prevention and Control (ECDC). COVID-19 situation board. Available: https://covid19.eu/public/extensions/COVID-19/COVID-19.html#subnational-transmission-tab [Accessed 10 Mar 2021].
28 Bollettino-sorveglianza-integra-COVID-19_30 giugno, 2020. Available: https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza- come-integrata-COVID-19_30-giugno-2020.pdf [Accessed 10 Mar 2021].
29 Bollettino Epidemiologico Regioni Puglia. Epidemia COVID-19, 10 marzo, 2021. Available: https://www.regione.puglia.it/documents/65725/216593/Bollettino+Covid_10032021.pdf/6fcf1d87-a820-25c9-9832-2585c0f50097?Expires=1653827557&Signature=8AWO%2FGZ1cOm5E2Gwty%2BqHzNj%2BZdZC8K%3D [Accessed 10 Mar 2021].
30 Karlberg J, Chong DSY, Lai WYY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Am J Epidemiol 2004;159:229–31.
31 Alghamdi IG, Hussain II, Almalki SS, et al. The pattern of middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of health. Int J Gen Med 2014;7:417–23.
32 Penna C, Mercurio V, Tocchetti CG, et al. Sex-Related differences in COVID-19 lethality. Br J Pharmacol 2020;177:4375–85.
33 Anastassopoulou C, Gkizarioti Z, Patrinos GP, et al. Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Hum Genomics 2020;14:40.
34 Haitao T, Vermunt JV, Abeykoon J, et al. COVID-19 and sex differences: mechanisms and biomarkers. Mayo Clin Proc 2020;95:2189–203.
35 Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020;588:315–20.
36 Takahashi T, Iwasaki A. Sex differences in immune responses. Science 2021;371:347–8.
37 Liang X. Is COVID-19 more severe in older men? Postgrad Med J 2020;96:426.
38 Bhopal SS, Bhopal R. Sex differential in COVID-19 mortality varies markedly by age. Lancet 2020;396:532–3.
39 Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature 2020;587:610–2.
40 Wenham C, Smith J, Morgan R, et al. COVID-19: the gendered impacts of the outbreak. Lancet 2020;395:846–8.
41 Sharma G, Volgman AS, Michos ED. Sex differences in mortality from COVID-19 pandemic: are men vulnerable and women protected? JACC Case Rep 2020;2:1407–10.